Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Summary

The goal of this clinical research study is to learn if blinatumomab can help to control Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be studied. This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of acute lymphoblastic leukemia (ALL). It is investigational to use blinatumomab to treat patients with RT. The study doctor can explain how the study drug is designed to work. Up to 21 participants will be enrolled in this study. All will take part at MD Anderson.

Timeline

Start

2017-06-22

Primary completion

2022-02-11

Completion

2022-02-11

Publications

• Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia. 2022 Sep;36(9):2228-2232. doi: 10.1038/s41375-022-01649-3. Epub 2022 Aug 8.

Drugs

Indications